


# Superior Weight Loss and Glycemic Control Compared to Insulin Therapy

**EXENATIDE ONCE WEEKLY**

## DURATION 3 Top-line Results

- > Exenatide once weekly delivered statistically significant improvements in glycemic control and body weight
- > Evaluable Patients treated with exenatide once weekly experienced A1c reductions of 1.5% compared to 1.3% for Lantus®
- > Results support superiority of exenatide once weekly even though Lantus was administered in variable doses determined by patient blood sugar levels




# Compelling Evidence Supporting Superiority Relative to Commonly Prescribed Oral Agents

**EXENATIDE ONCE WEEKLY**

## DURATION 2 Results

> Exenatide once weekly achieved statistically significant HbA1c and weight reductions relative to Januvia™ (sitagliptin) or Actos® (pioglitazone)

**Change in HbA1c % at 26 Weeks vs. maximum doses of Januvia or Actos**



**Change in weight at 26 Weeks vs. maximum doses of Januvia or Actos**

